My SciELO
Custom servicesServices on Demand
Journal
Article
Spanish (pdf)
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO 
Access statistics
Related links
Cited by Google 
Similars in
SciELO 
Similars in Google
Share
Permalink
Ars Pharmaceutica (Internet)
On-line version ISSN 2340-9894
Abstract
SOTOCA-MOMBLONA, José Miguel et al. Effectiveness of hepatitis C antiviral treatment in attended patients from the outpatient pharmacy consultation. Ars Pharm [online]. 2020, vol.61, n.1, pp.45-47. Epub July 20, 2020. ISSN 2340-9894. https://dx.doi.org/10.30827/ars.v61i1.11672.
Objective:
To determine the effectiveness of the treatment of chronic hepatitis C determined as the sustained viral response at 12 weeks (SVR12) after the end of treatment with direct-acting antiviral drugs (DAA) (glecaprevir/pibrentasvir, sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir and grazoprevir/elbasvir) in attended patients from the outpatient pharmacy consultation.
Method:
a retrospective study that includes patients attended by pharmacists who started treatment between December 1, 2017 and May 31, 2018. Demographic data, disease, adherence and treatment consultations were recorded (interactions, adverse effects and others).
Results:
Two hundred and five patients were included, with different hepatitis C genotypes, fibrosis states and morbidity levels. Effectiveness was 99.5%, similar to that of clinical trials.
Conclusions:
These results resemble those obtained in pharmacy consultations in the United States, operating for more than ten years.
Keywords : Pharmaceutical care; Hepatitis C; Effectiveness.
